RESUMEN
Purpose: Rope bamboo (Gigantochloa apus) is traditionally used for medicinal purposes, and extracts from stem leaves and shoots have been shown to possess antioxidant and anti-inflammatory activity. Thus, this study looked at the potential compounds present in and the usefulness of Rope bamboo liquid smoke preparations in the wound healing process in mice. Methods: The fingerprinting of the liquid smoke was done by liquid chromatography-mass spectrometry. In-vivo experiments were conducted to observe the diameter and percentage of wound healing in mice for 14 days using topical formulations containing liquid smoke concentrations of 100%, 50%, 25%, positive control and negative control. Statistical analyses were conducted using the Kruskal-Wallis test and Spearman correlation. Results: The phytochemical fingerprint showed the presence of alkaloids, flavonoids, vitamins, phenols, and lipids. The 100% undiluted liquid smoke accelerated wound healing faster compared to 50% and 25% dilutions. The differences in wound diameters were statistically significant across treatments having a p-value of 0.020 and dose-dependent (p = 0.029). Conclusion: Liquid smoke acceleration of the wound healing process was dose-dependent compared to controls. This dose-dependency indicates that the wound healing effects were probably due to the anti-inflammatory, antioxidant, and antimicrobial activities of the elucidated constituents of Rope bamboo liquid smoke.
RESUMEN
Most of the individuals who die of malaria in sub-Saharan Africa are children. It is, therefore, important for this age group to have access to the right treatment and correct dose. Artemether-lumefantrine is one of the fixed dose combination therapies that was approved by the World Health Organization to treat malaria. However, the current recommended dose has been reported to cause underexposure or overexposure in some children. The aim of this article was, therefore, to estimate the doses that can mimic adult exposure. The availability of more and reliable pharmacokinetic data is essential to accurately estimate appropriate dosage regimens. The doses in this study were estimated using the physiological information from children and some pharmacokinetic data from adults due to the lack of pediatric pharmacokinetic data in the literature. Depending on the approach that was used to calculate the dose, the results showed that some children were underexposed, and others were overexposed. This can lead to treatment failure, toxicity, and even death. Therefore, when designing a dosage regimen, it is important to know and include the distinctions in physiology at various phases of development that influence the pharmacokinetics of various drugs in order to estimate the dose in young children. The physiology at each time point during the growth of a child may influence how the drug is absorbed, gets distributed, metabolized, and eliminated. From the results, there is a very clear need to conduct a clinical study to further verify if the suggested (i.e., 0.34 mg/kg for artemether and 6 mg/kg for lumefantrine) doses could be clinically efficacious.